U.S. Markets closed

Biogen shares plunge after it scraps Alzheimer’s treatment

Shares of Biogen tanked on Thursday after it announced its ending late-stage trials for a experimental Alzheimer’s drug. Yahoo Finance's Scott Gamm caught up with Sarge986 LLC President Stephen Guilfoyle to discuss the news.